Showing results (391-400 of 403) with videos related to

Sort By:
Pageof 41
Arthritis Research & Therapy|January 31, 2025
Differences in the response to TNF inhibitors at distinct joint locations in patients with psoriatic arthritis: results from nine European registriesAdrian Ciurea, Seraphina Kissling, Andrea Götschi, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 17, 2023
Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration NetworkPasoon Hellamand, Marleen G H van de Sande, Lykke M Ørnbjerg, et al.
Rheumatology (Oxford, England)|December 23, 2021
European bio-naïve spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and responseSara Nysom Christiansen, Lykke Midtbøll Ørnbjerg, Simon Horskjær Rasmussen, et al.
Annals of the Rheumatic Diseases|July 13, 2026
Influence of national socioeconomic status on treatment retention and disease activity in psoriatic arthritis and axial spondyloarthritis: evidence over 2 years in 13 European countriesBrigitte Michelsen, Christos Polysopoulos, Michael J Nissen, et al.
Health Policy (Amsterdam, Netherlands)|April 17, 2025
Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across EuropeBrigitte Michelsen, Mikkel Østergaard, Michael John Nissen, et al.
Joint Bone Spine|April 6, 2024
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatmentLykke Midtbøll Ørnbjerg, Cecilie Heegaard Brahe, Louise Linde, et al.
Rheumatology (Oxford, England)|July 23, 2024
Sex differences in patient-reported outcome measures and the association with clinical factors in axial spondyloarthritis patients treated with tumour necrosis factor inhibitorsPasoon Hellamand, Marleen G H van de Sande, Michael T Nurmohamed, et al.
The Lancet. Rheumatology|March 25, 2026
Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trialJon Lampa, Dan Nordström, Ronald van Vollenhoven, et al.
BMJ (Clinical Research Ed.)|December 3, 2020
Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trialMerete Lund Hetland, Espen A Haavardsholm, Anna Rudin, et al.
RMD Open|May 7, 2026
Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritisZohra Faizy Ahmadzay, Lykke Midtbøll Ørnbjerg, Mikkel Østergaard, et al.
Pageof 41